RATIONALE: In recent work, we have demonstrated a crucial role of mast cells in the development of viral myocarditis. Viral infection could lead to increased synthesis of free immunoglobulin light chains (FLC) and our earlier work showed that FLC can trigger mast cell activation. OBJECTIVE: We studied the possible involvement of FLC in the pathogenesis of viral myocarditis, and therapeutic effects of FLC using an animal model of viral myocarditis. METHODS AND RESULTS: DBA/2 mice were inoculated intraperitoneally with encephalomyocarditis (EMC) virus. Serum levels and concentrations in the heart of kappa FLC on day 14 in mice inoculated with EMC virus were significantly increased compared with controls. Myocardial viral concentration was significantly inhibited, the area of myocardial lesions was smaller in mice treated with kappa or lambda FLC, and survival of mice given FLC significantly improved. In contrast, an FLC antagonist deteriorated myocarditis. kappa and lambda FLC chains inhibited EMC viral replication in human amnion cells in vitro. lambda FLC significantly increased the gene expression of interleukin-10 in the heart which was previously shown to improve viral myocarditis when given exogenously. FLC also tended to increase the gene expressions of interferon-alpha and -gamma in the heart mice. CONCLUSIONS: FLC have antiviral and antiinflammatory effects and improved viral myocarditis in mice. FLC may be promising agents for the treatment of viral myocarditis.
RATIONALE: In recent work, we have demonstrated a crucial role of mast cells in the development of viral myocarditis. Viral infection could lead to increased synthesis of free immunoglobulin light chains (FLC) and our earlier work showed that FLC can trigger mast cell activation. OBJECTIVE: We studied the possible involvement of FLC in the pathogenesis of viral myocarditis, and therapeutic effects of FLC using an animal model of viral myocarditis. METHODS AND RESULTS: DBA/2 mice were inoculated intraperitoneally with encephalomyocarditis (EMC) virus. Serum levels and concentrations in the heart of kappa FLC on day 14 in mice inoculated with EMC virus were significantly increased compared with controls. Myocardial viral concentration was significantly inhibited, the area of myocardial lesions was smaller in mice treated with kappa or lambda FLC, and survival of mice given FLC significantly improved. In contrast, an FLC antagonist deteriorated myocarditis. kappa and lambda FLC chains inhibited EMC viral replication in human amnion cells in vitro. lambda FLC significantly increased the gene expression of interleukin-10 in the heart which was previously shown to improve viral myocarditis when given exogenously. FLC also tended to increase the gene expressions of interferon-alpha and -gamma in the heart mice. CONCLUSIONS: FLC have antiviral and antiinflammatory effects and improved viral myocarditis in mice. FLC may be promising agents for the treatment of viral myocarditis.
Authors: Giuseppe Di Noto; Lucia Paolini; Andrea Zendrini; Annalisa Radeghieri; Luigi Caimi; Doris Ricotta Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Tom Groot Kormelink; Annie Pardo; Karen Knipping; Ivette Buendía-Roldán; Carolina García-de-Alba; Bart R Blokhuis; Moises Selman; Frank A Redegeld Journal: PLoS One Date: 2011-09-28 Impact factor: 3.240
Authors: Marco Thio; Tom Groot Kormelink; Marcel J Fischer; Bart R Blokhuis; Frans P Nijkamp; Frank A Redegeld Journal: PLoS One Date: 2012-07-20 Impact factor: 3.240
Authors: Oliver Zimmermann; Jörg M Homann; Anna Bangert; Anna-Maria Müller; Georgi Hristov; Stefan Goeser; Juliane M Wiehe; Stefan Zittrich; Wolfgang Rottbauer; Jan Torzewski; Gabriele Pfitzer; Hugo A Katus; Ziya Kaya Journal: J Am Heart Assoc Date: 2012-12-19 Impact factor: 5.501